Using the Fissios App to Improve Recovery After Lung Surgery

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This trial investigates the effectiveness of the Fissios App, a smartphone tool designed to enhance respiratory physiotherapy, in reducing post-operative complications for patients undergoing lung resection surgery due to non-small cell lung cancer. Participants will be randomly assigned to either a control group receiving standard physiotherapy or an intervention group using the Fissios App alongside their physiotherapy. The study aims to assess improvements in post-operative outcomes and overall quality of life over a 90-day follow-up period. A total of 560 participants will be recruited across multiple centers for this multicenter, randomized, controlled trial.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Patients over 18 years of age.
2. Indication for lung resection surgery due to diagnostic suspicion or histopathological diagnosis of non-small cell lung carcinoma.
3. Anatomical lung resection surgery: anatomical segmental resection, lobectomies or pneumonectomies, using a conventional or minimally invasive approach (VATS, RATS).
4. The patient has a smart mobile device compatible with the Fissios App©, has the ability or has the support to use it.
5. Willingness and commitment to participate in the study.
6. Ability to complete the informed consent to participate in the study.

Exclusion Criteria:

1. Medical contraindication to perform respiratory physiotherapy exercises.
2. Not possessing a smart mobile device compatible with Fissios App©.
3. Inability of the patient to perform the exercises, either due to a physical or psychological impediment.
4. Inability to complete the informed consent form for participation in the study.
5. Refusal to participate in the study.

Where it's running

• Hospital Clínico San Carlos
  Madrid, Madrid, Spain Recruiting

Study contacts

• Principal investigator: Carlos A Fraile Olivero, MD, PhD — Hospital San Carlos, Madrid
• Study coordinator: Carlos A Fraile Olivero, MD, PhD
• Email: carlosalfredo.fraile@salud.madrid.org
• Phone: +34917043708

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Wearable device for early warning of postoperative complications after thoracic surgery

  A wearable device is used to see if continuous monitoring can spot early signs of problems after thoracic surgery in adults.

  Recruiting Tongji Hospital · Wuhan, Hubei · NCT07646730

• Family-centered care to reduce emergency delirium in children after surgery

  This study tests if having family members involved during surgery can help young children aged 2-6 experience less confusion and distress when waking up from anesthesia.

  Recruiting Second Affiliated Hospital of Wenzhou Medical University · Wenzhou, Zhejiang · NCT06092671

• Patient-specific MRD liquid biopsy for resected NSCLC

  This study tests a personalized MRD blood and bronchial washing test after surgery to see if it can signal recurrence earlier in people with resected NSCLC.

  Recruiting Yonsei University · Yongin-si, Gyeonggi-do and 2 other locations · NCT07921888

• Osimertinib Plus SRS/SRT for EGFR-Mutant NSCLC with Symptomatic Brain Metastases

  This study tests whether adding targeted brain radiotherapy to osimertinib helps control brain metastases in adults with EGFR-mutant NSCLC and neurological symptoms.

  Recruiting Phase 2 Cho Ray Hospital · Ho Chi Minh City · NCT07911449

• Prehabilitation with Resistance, Aerobic, or Both Before Colorectal Surgery

  Four pre-surgery exercise options (resistance, aerobic, both, or none) will be tested to see which best reduces complications after colorectal cancer surgery.

  Recruiting Semmelweis University · Budapest · NCT07896174

• Dato-DXd in solid tumors (Urothelial Cancer and KRAS-mutant NSCLC) in two sub-studies

  This study tests Datopotamab Deruxtecan (Dato-DXd) alone or with other cancer drugs in people with urothelial cancer or KRAS-mutant non-small cell lung cancer.

  Recruiting Phase 1/2 Daiichi Sankyo · Taichung · NCT07890714

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.